{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,28]],"date-time":"2026-10-28T22:57:10Z","timestamp":1793228230668,"version":"4.5.0"},"reference-count":32,"publisher":"American Society of Clinical Oncology (ASCO)","issue":"26","content-domain":{"domain":["ascopubs.org"],"crossmark-restriction":true},"short-container-title":["J Clin Oncol"],"published-print":{"date-parts":[[2026,9,10]]},"abstract":"<jats:sec>\n                    <jats:title>PURPOSE<\/jats:title>\n                    <jats:p>\n                      To evaluate the efficacy and safety of the cluster of differentiation 47\u2013targeted antibody magrolimab plus azacitidine (Magro\/Aza) versus azacitidine alone in treatment-na\u00efve patients with higher-risk myelodysplastic syndromes (MDS) in the phase III ENHANCE study (ClinicalTrials.gov identifier:\n                      <jats:ext-link xmlns:xlink=\"http:\/\/www.w3.org\/1999\/xlink\" ext-link-type=\"uri\" xlink:href=\"https:\/\/www.clinicaltrials.gov\/ct2\/show\/NCT04313881\">NCT04313881<\/jats:ext-link>\n                      ).\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>METHODS<\/jats:title>\n                    <jats:p>\n                      Based on the Revised International Prognostic Scoring System, patients with intermediate- to very-high-risk MDS were randomly assigned to receive Magro (1 mg\/kg on days [D]1 and 4; 15 mg\/kg on D8; 30 mg\/kg on D11 and D15, and then once per week for five doses, followed by 30 mg\/kg maintenance doses once every 2 weeks)\/Aza (75 mg\/m\n                      <jats:sup>2<\/jats:sup>\n                      daily on D1-7 or on D1-5 and 8-9 in 28-day cycles) or matched placebo plus azacitidine (Placebo\/Aza). Dual primary end points were complete remission (CR) rate (per 2006 International Working Group criteria) and overall survival (OS).\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>RESULTS<\/jats:title>\n                    <jats:p>\n                      At final analysis, 539 patients were randomly assigned to Magro\/Aza (n = 268) or Placebo\/Aza (n = 271) arms. Baseline characteristics were generally well balanced between treatment arms. In the Magro\/Aza versus Placebo\/Aza arms, the CR rate was 21.3% versus 23.6% (odds ratio, 0.876 [95% CI, 0.585 to 1.312];\n                      <jats:italic toggle=\"yes\">P<\/jats:italic>\n                      = .5218), and median OS was 15.9 versus 18.6 months (hazard ratio, 1.203 [95% CI, 0.947 to 1.528];\n                      <jats:italic toggle=\"yes\">P<\/jats:italic>\n                      = .1299). Magro\/Aza had a higher incidence of grade \u22653 adverse events (AEs; 92.8%\n                      <jats:italic toggle=\"yes\">v<\/jats:italic>\n                      79.2%), AE-associated study drug discontinuations (24.0%\n                      <jats:italic toggle=\"yes\">v<\/jats:italic>\n                      12.1%), serious AEs (71.9%\n                      <jats:italic toggle=\"yes\">v<\/jats:italic>\n                      51.5%), and fatal AEs (15.2%\n                      <jats:italic toggle=\"yes\">v<\/jats:italic>\n                      9.8%) versus Placebo\/Aza.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>CONCLUSION<\/jats:title>\n                    <jats:p>ENHANCE did not meet the primary end points of CR rate and OS, and showed more frequent severe AEs in patients treated in the Magro\/Aza arm.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1200\/jco-25-00617","type":"journal-article","created":{"date-parts":[[2026,7,13]],"date-time":"2026-07-13T19:59:12Z","timestamp":1783972752000},"page":"2529-2542","update-policy":"https:\/\/doi.org\/10.1200\/crossmark","source":"Crossref","is-referenced-by-count":2,"title":["Magrolimab Plus Azacitidine Versus Placebo Plus Azacitidine in Patients With Untreated Higher-Risk Myelodysplastic Syndromes: The Phase III ENHANCE Study"],"prefix":"10.1200","volume":"44","clinical-trial-number":[{"clinical-trial-number":"nct04313881","registry":"10.18810\/clinical-trials-gov"}],"author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-0504-8233","authenticated-orcid":true,"given":"David A.","family":"Sallman","sequence":"first","affiliation":[{"name":"Moffitt Cancer Center, Tampa, FL"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3631-2482","authenticated-orcid":true,"given":"Guillermo","family":"Garcia-Manero","sequence":"additional","affiliation":[{"name":"The University of Texas MD Anderson Cancer Center, Houston, TX"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7103-373X","authenticated-orcid":true,"given":"Naval","family":"Daver","sequence":"additional","affiliation":[{"name":"The University of Texas MD Anderson Cancer Center, Houston, TX"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6653-3518","authenticated-orcid":true,"given":"Camille N.","family":"Abboud","sequence":"additional","affiliation":[{"name":"Washington University School of Medicine, St Louis, MO"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8992-9390","authenticated-orcid":true,"given":"Eytan","family":"Stein","sequence":"additional","affiliation":[{"name":"Memorial Sloan Kettering Cancer Center, New York, NY"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1898-9836","authenticated-orcid":true,"given":"Karilyn","family":"Larkin","sequence":"additional","affiliation":[{"name":"The Ohio State University, Columbus, OH"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4326-0748","authenticated-orcid":true,"given":"Anna B.","family":"Halpern","sequence":"additional","affiliation":[{"name":"Fred Hutchinson Cancer Center and University of Washington, Seattle, WA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2813-6781","authenticated-orcid":true,"given":"Shannon R.","family":"McCurdy","sequence":"additional","affiliation":[{"name":"Perelman School of Medicine of the University of Pennsylvania, Philadelphia, PA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8226-471X","authenticated-orcid":true,"given":"Monzr M.","family":"Al Malki","sequence":"additional","affiliation":[{"name":"City of Hope National Medical Center, Duarte, CA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9889-2611","authenticated-orcid":true,"given":"Guru","family":"Subramanian Guru Murthy","sequence":"additional","affiliation":[{"name":"Medical College of Wisconsin, Milwaukee, WI"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5481-4339","authenticated-orcid":true,"given":"Lewis R.","family":"Silverman","sequence":"additional","affiliation":[{"name":"Icahn School of Medicine at Mount Sinai and Tisch Cancer Institute, New York, NY"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9168-3203","authenticated-orcid":true,"given":"Richard A.","family":"Larson","sequence":"additional","affiliation":[{"name":"University of Chicago, Chicago, IL"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peter","family":"Greenberg","sequence":"additional","affiliation":[{"name":"Stanford University Cancer Center, Palo Alto, CA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0312-3412","authenticated-orcid":true,"given":"Ivana","family":"Gojo","sequence":"additional","affiliation":[{"name":"Johns Hopkins University School of Medicine, Sidney Kimmel Comprehensive Cancer Center, Baltimore, MD"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6612-3535","authenticated-orcid":true,"given":"Tomasz","family":"Wrobel","sequence":"additional","affiliation":[{"name":"Wroclaw Medical University, Wroclaw, Poland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1863-3239","authenticated-orcid":true,"given":"Uwe","family":"Platzbecker","sequence":"additional","affiliation":[{"name":"University Hospital Carl Gustav Carus, Dresden, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9108-3088","authenticated-orcid":true,"given":"Cecily","family":"Forsyth","sequence":"additional","affiliation":[{"name":"Jarrett Street Specialist Centre, Gosford, NSW, Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9779-6217","authenticated-orcid":true,"given":"Pankit","family":"Vachhani","sequence":"additional","affiliation":[{"name":"O'Neal Comprehensive Cancer Center, University of Alabama at Birmingham, Birmingham, AL"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mei","family":"Dong","sequence":"additional","affiliation":[{"name":"Gilead Sciences, Inc, Foster City, CA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jiang","family":"Shao","sequence":"additional","affiliation":[{"name":"Gilead Sciences, Inc, Foster City, CA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2019-6560","authenticated-orcid":true,"given":"Lisa D.S.","family":"Johnson","sequence":"additional","affiliation":[{"name":"Gilead Sciences, Inc, Foster City, CA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anderson","family":"Tan","sequence":"additional","affiliation":[{"name":"Gilead Sciences, Inc, Foster City, CA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Calvin","family":"Lee","sequence":"additional","affiliation":[{"name":"Gilead Sciences, Inc, Foster City, CA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5399-5844","authenticated-orcid":true,"given":"Parul","family":"Doshi","sequence":"additional","affiliation":[{"name":"Gilead Sciences, Inc, Foster City, CA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3931-0914","authenticated-orcid":true,"given":"Paresh","family":"Vyas","sequence":"additional","affiliation":[{"name":"MRC Weatherall Institute of Molecular Medicine, Oxford University Hospitals NHS Foundation Trust, Oxford, United Kingdom"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7514-3298","authenticated-orcid":true,"given":"Andrew H.","family":"Wei","sequence":"additional","affiliation":[{"name":"Peter MacCallum Cancer Centre, Royal Melbourne Hospital, Walter and Eliza Hall Institute of Medical Research, and University of Melbourne, Melbourne, VIC, Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"233","reference":[{"key":"e_1_3_11_2_2","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2012-03-420489"},{"key":"e_1_3_11_3_2","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2016-02-700054"},{"key":"e_1_3_11_4_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.bbmt.2012.01.009"},{"key":"e_1_3_11_5_2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.20.02724"},{"key":"e_1_3_11_6_2","unstructured":"National Cancer Institute: Surveillance Epidemiology and End Results Program. Cancer statistics explorer network: Myelodysplastic syndromes (MDS) \u2014 Recent trends in SEER age-adjusted incidence rates 2001-2021. https:\/\/seer.cancer.gov\/statistics-network\/explorer\/application.html"},{"key":"e_1_3_11_7_2","doi-asserted-by":"publisher","DOI":"10.1182\/bloodadvances.2022007334"},{"key":"e_1_3_11_8_2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2002.04.117"},{"key":"e_1_3_11_9_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.clml.2022.11.002"},{"key":"e_1_3_11_10_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.leukres.2014.03.012"},{"key":"e_1_3_11_11_2","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2021-146154"},{"key":"e_1_3_11_12_2","doi-asserted-by":"publisher","DOI":"10.1182\/bloodadvances.2021005487"},{"key":"e_1_3_11_13_2","unstructured":"Aprea Therapeutics announces results of primary endpoint from phase 3 trial of eprenetapopt in TP53 mutant myelodysplastic syndromes (MDS) 2020. https:\/\/ir.aprea.com\/news-releases\/news-release-details\/aprea-therapeutics-announces-results-primary-endpoint-phase-3"},{"key":"e_1_3_11_14_2","unstructured":"Onconova Therapeutics announces topline results from the pivotal phase 3 INSPIRE trial 2020. https:\/\/investor.onconova.com\/news-releases\/news-release-details\/onconova-therapeutics-announces-topline-results-pivotal-phase-3"},{"key":"e_1_3_11_15_2","unstructured":"Takeda provides update on phase 3 PANTHER (Pevonedistat-3001) trial 2021. https:\/\/www.takeda.com\/newsroom\/newsreleases\/2021\/takeda-provides-update-on-phase-3-panther-pevonedistat-3001-trial\/"},{"key":"e_1_3_11_16_2","doi-asserted-by":"publisher","DOI":"10.1182\/blood.2024024245"},{"key":"e_1_3_11_17_2","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2019.01380"},{"key":"e_1_3_11_18_2","doi-asserted-by":"crossref","first-page":"e0137345","DOI":"10.1371\/journal.pone.0137345","article-title":"Pre-clinical development of a humanized anti-CD47 antibody with anti-cancer therapeutic potential","volume":"10","author":"Liu J","year":"2015","unstructured":"Liu J, Wang L, Zhao F, et al: Pre-clinical development of a humanized anti-CD47 antibody with anti-cancer therapeutic potential. PLoS ONE 10:e0137345, 2015","journal-title":"PLoS ONE"},{"key":"e_1_3_11_19_2","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.1305569110"},{"key":"e_1_3_11_20_2","doi-asserted-by":"publisher","DOI":"10.1126\/scitranslmed.3001375"},{"key":"e_1_3_11_21_2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.22.01794"},{"key":"e_1_3_11_22_2","doi-asserted-by":"publisher","DOI":"10.1182\/bloodadvances.2023010417"},{"key":"e_1_3_11_23_2","doi-asserted-by":"publisher","DOI":"10.1158\/2159-8290.CD-22-0332"},{"key":"e_1_3_11_24_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1716863"},{"key":"e_1_3_11_25_2","doi-asserted-by":"publisher","DOI":"10.1182\/blood.2023021579"},{"key":"e_1_3_11_26_2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.21.01546"},{"key":"e_1_3_11_27_2","doi-asserted-by":"publisher","DOI":"10.1016\/S2152-2650(25)02083-X"},{"key":"e_1_3_11_28_2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.20.02810"},{"key":"e_1_3_11_29_2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.20.01659"},{"key":"e_1_3_11_30_2","doi-asserted-by":"publisher","DOI":"10.1056\/EVIDoa2200008"},{"key":"e_1_3_11_31_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1611604"},{"key":"e_1_3_11_32_2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.23.00866"},{"key":"e_1_3_11_33_2","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2024-200541"}],"container-title":["Journal of Clinical Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/ascopubs.org\/doi\/pdfdirect\/10.1200\/JCO-25-00617","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,9,4]],"date-time":"2026-09-04T21:59:36Z","timestamp":1788559176000},"score":1,"resource":{"primary":{"URL":"https:\/\/ascopubs.org\/doi\/10.1200\/JCO-25-00617"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,9,10]]},"references-count":32,"journal-issue":{"issue":"26","published-print":{"date-parts":[[2026,9,10]]}},"alternative-id":["10.1200\/JCO-25-00617"],"URL":"https:\/\/doi.org\/10.1200\/jco-25-00617","relation":{},"ISSN":["0732-183X","1527-7755"],"issn-type":[{"value":"0732-183X","type":"print"},{"value":"1527-7755","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,9,10]]},"assertion":[{"value":"2025-03-18","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2026-02-24","order":1,"name":"revised","label":"Revised","group":{"name":"publication_history","label":"Publication History"}},{"value":"2026-04-15","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2026-07-13","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}